PharmaCyte Biotech Inc has successfully monetized its stake in Femasys, increasing its cash and marketable securities from $13.3 million to approximately $20 million. This significant boost in financial resources enhances the company's stability and investment capacity.
CEO Josh Silverman emphasized that this monetization validates PharmaCyte's strategic and disciplined approach to capital allocation. The company plans to continue pursuing value-accretive investment opportunities to enhance shareholder returns.
Despite the improved financial position, PharmaCyte's stock trades at $0.65 per share with around 6.8 million shares outstanding, reflecting cautious market sentiment regarding its long-term value. The company remains committed to strict operational management and capital deployment strategies to further enhance shareholder returns.
PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
